Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy AnaptysBio stock | $28.55

Learn how to easily invest in AnaptysBio stock.

AnaptysBio Inc is a biotechnology business based in the US. AnaptysBio shares (ANAB) are listed on the NASDAQ and all prices are listed in US Dollars. AnaptysBio employs 94 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in AnaptysBio

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ANAB – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

AnaptysBio stock price (NASDAQ: ANAB)

Use our graph to track the performance of ANAB stocks over time.

AnaptysBio shares at a glance

Information last updated 2021-10-16.
Latest market close$28.55
52-week range$18.30 - $35.86
50-day moving average $26.91
200-day moving average $24.88
Wall St. target price$35.33
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.32

Buy AnaptysBio shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
$20 per year
Financial advice powered by relationships, not commissions.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy AnaptysBio stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

AnaptysBio price performance over time

Historical closes compared with the close of $28.55 from 2021-10-22

1 week (2021-10-12) N/A
1 month (2021-09-23) 1.64%
3 months (2021-07-23) 10.87%
6 months (2021-04-23) 20.92%
1 year (2020-10-23) 10.96%
2 years (2019-10-23) -24.09%
3 years (2018-10-23) 76.5
5 years (2016-10-19) N/A

AnaptysBio financials

Revenue TTM $101.3 million
Gross profit TTM $-5,025,000
Return on assets TTM -1.49%
Return on equity TTM -2.27%
Profit margin -8.6%
Book value $14.06
Market capitalisation $786.5 million

TTM: trailing 12 months

Shorting AnaptysBio shares

There are currently 2.6 million AnaptysBio shares held short by investors – that's known as AnaptysBio's "short interest". This figure is 7.9% down from 2.8 million last month.

There are a few different ways that this level of interest in shorting AnaptysBio shares can be evaluated.

AnaptysBio's "short interest ratio" (SIR)

AnaptysBio's "short interest ratio" (SIR) is the quantity of AnaptysBio shares currently shorted divided by the average quantity of AnaptysBio shares traded daily (recently around 158000.30826141). AnaptysBio's SIR currently stands at 16.22. In other words for every 100,000 AnaptysBio shares traded daily on the market, roughly 16220 shares are currently held short.

However AnaptysBio's short interest can also be evaluated against the total number of AnaptysBio shares, or, against the total number of tradable AnaptysBio shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case AnaptysBio's short interest could be expressed as 0.09% of the outstanding shares (for every 100,000 AnaptysBio shares in existence, roughly 90 shares are currently held short) or 0.1502% of the tradable shares (for every 100,000 tradable AnaptysBio shares, roughly 150 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against AnaptysBio.

Find out more about how you can short AnaptysBio stock.

AnaptysBio share dividends

We're not expecting AnaptysBio to pay a dividend over the next 12 months.

AnaptysBio share price volatility

Over the last 12 months, AnaptysBio's shares have ranged in value from as little as $18.3 up to $35.855. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while AnaptysBio's is 0.0516. This would suggest that AnaptysBio's shares are less volatile than average (for this exchange).

AnaptysBio overview

AnaptysBio, Inc. , a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. The company's products include Imsidolimab, an IL-36R antibody that inhibits the interleukin-36 receptor for the treatment of various dermatological inflammatory diseases; ANB030, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through ANB030 treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. It also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. AnaptysBio, Inc. has a collaboration and license agreement with TESARO, Inc. and Celgene Corporation; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation.

Frequently asked questions

What percentage of AnaptysBio is owned by insiders or institutions?
Currently 0.554% of AnaptysBio shares are held by insiders and 105.949% by institutions.
How many people work for AnaptysBio?
Latest data suggests 94 work at AnaptysBio.
When does the fiscal year end for AnaptysBio?
AnaptysBio's fiscal year ends in December.
Where is AnaptysBio based?
AnaptysBio's address is: 10421 Pacific Center Court, San Diego, CA, United States, 92121
What is AnaptysBio's ISIN number?
AnaptysBio's international securities identification number is: US0327241065
What is AnaptysBio's CUSIP number?
AnaptysBio's Committee on Uniform Securities Identification Procedures number is: 032724106

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site